©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Escherichia coli DNA Topoisomerase III Is a Site-specific DNA Binding Protein That Binds Asymmetrically to Its Cleavage Site (*)

(Received for publication, April 12, 1995; and in revised form, June 21, 1995)

Hong Liang Zhang (1) Swati Malpure (2) Russell J. DiGate (1) (2) (3)(§)

From the  (1)Molecular and Cell Biology Program. University of Maryland at Baltimore, the (2)Department of Pharmaceutical Science, University of Maryland at Baltimore School of Pharmacy, and (3)Medical Biotechnology Center, Maryland Biotechnology Institute, University of Maryland, Baltimore, Maryland 21201

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The binding of DNA topoisomerase III (Topo III) to a single-stranded DNA substrate containing a strong cleavage site has been examined. The minimal substrate requirement for Topo III-catalyzed cleavage has been determined to consist of 7 bases: 6 bases 5` to the cleavage site and only 1 base 3` to the site. Nuclease P1 protection experiments indicate that the enzyme also binds to its substrate asymmetrically, protecting 12 bases 5` to the cleavage site and only 2 bases 3` to the cleavage site. A catalytically inactive mutant of Topo III shows the same protection pattern as the active polypeptide, indicating that Topo III is a site-specific binding protein as well as a topoisomerase. Consistent with this view, an oligonucleotide containing a cleavage site is a more effective inhibitor and is bound more efficiently by Topo III than an oligonucleotide without a cleavage site.


INTRODUCTION

Escherichia coli has been shown to possess four DNA topoisomerase activities. Two type I enzymes, DNA topoisomerase I (Topo I) (^1)(1) and DNA topoisomerase III(2, 3, 4) , have been purified and characterized. In addition, two type II enzymes, DNA topoisomerase II (DNA gyrase) (5) and DNA topoisomerase IV (Topo IV)(6) , have also been purified and characterized. The role of these enzymes in DNA metabolism has been defined by studies, both genetic and in vitro. For example, DNA gyrase and Topo I have been shown to be involved in the maintenance of superhelical density of the E. coli chromosome(7) . In addition, there is also evidence that DNA gyrase is involved in the terminal stages of DNA replication (8) . Topo IV (9, 10) and Topo III (4, 11) have been shown to be potent decatenases in vitro, and it has been proposed that these enzymes are involved in the separation of nascent daughter chromosomes during the terminal stages of DNA replication. In addition, it has also been shown that DNA gyrase, Topo IV, and Topo III can support DNA polymerase chain elongation during the replication of plasmid DNA in vitro(12) . The apparent redundant functions of these enzymes emphasizes the importance of these enzymes in DNA metabolism.

A model termed ``sign inversion'' (13) has been proposed that describes a unified mechanism for both type I and type II bacterial topoisomerases. In this model, a topoisomerase binds to its substrate (either single-stranded DNA for a type I enzyme or double-stranded DNA for a type II enzyme), catalyzes a strand break (either single (type I) or double (type II)) and strand passage event, and then reseals the break. The ``sign inversion'' model was originally proposed to explain the mechanism of bacterial DNA gyrase (a type II DNA topoisomerase); however, it has been extended to explain the mechanism of E. coli DNA topoisomerase I, a type I enzyme. It has been proposed that in the case of Topo I, the strand passage event can be thought to invert the sign of the two strands of the helix(14) , whereas, the strand passage event catalyzed by E. coli DNA gyrase, a type II enzyme, inverts the sign of a wrap of the entire helix(13, 15) .

Although there is evidence supporting this model as a whole, there is very little information regarding the properties of the individual steps of topoisomerase catalysis; therefore, our laboratory has set out to perform a detailed characterization of the mechanism of DNA topoisomerase III. In this report, the binding of Topo III to its substrate is examined, and a model for Topo III-catalyzed cleavage of DNA is proposed.


MATERIALS AND METHODS

DNA and Nucleotides

X-174 RFI DNA was purchased from Life Technologies, Inc. DNA oligonucleotides were prepared by the University of Maryland Biopolymer Laboratory. Radiolabeled nucleoside triphosphate was purchased from Amersham Corp.

Enzymes and Reagents

Acrylamide and agarose were from Life Technologies, Inc. Bacteriophage T4 polynucleotide kinase was from New England Biolabs Inc. E. coli Topo III was purified as previously described(16) . Nuclease P1 was purchased from Boehringer Mannheim.

Radiolabeling of Oligonucleotides

Oligonucleotides were 5`-end labeled using bacteriophage T4 polynucleotide kinase (Life Sciences) and [-P]ATP as per the manufacturer's recommendations. The labeled oligonucleotides were fractionated through a polyacrylamide gel. The region containing the labeled oligonucleotide was excised, and the DNA was isolated by direct elution of the fragment into 10 mM Tris-HCl (pH 7.5 at 22 °C), 1 mM EDTA. The radiolabeled oligonucleotides were diluted to a specific activity of 2000 cpm/pmol by the addition of excess unlabeled oligonucleotide.

Superhelical DNA Relaxation Assays

Superhelical DNA relaxation reaction mixtures (25 µl) contained 40 mM Hepes-KOH buffer (pH 8.0 at 22 °C), 1 mM magnesium acetate (pH 7.0), 0.1 mg/ml bovine serum albumin, 40% (v/v) glycerol, and 200 ng of X174 form I DNA. Reactions were incubated at 52 °C for 10 min, and the reaction products were separated and visualized as previously described(4) .

Oligonucleotide Gel Mobility Shift Assays

Reaction mixtures (10 µl) contained 40 mM Hepes-KOH buffer (pH 8.0 at 22 °C), 0.1 mg/ml bovine serum albumin, 1 mM magnesium acetate (pH 7.0), 12% glycerol, and 5 pmol of radiolabeled oligonucleotide. The reactions were incubated for 5 min at 37 °C, and the products were separated through a 10% polyacrylamide gel (30:0.8) using 0.5 times TBE as the running buffer. The gels were electrophoresed at 15 mA for 1.5 h, dried, and autoradiographed. The 45-base oligonucleotide used in the assay was 5`-CAGAATCAGAATGAGCCGCAACT TCGGGATGAAAATGCTCACAAT-3` where indicates the site of Topo III cleavage(16) . The 22-base oligonucleotide, containing a Topo III cleavage site, was the following subsequence of the 45-base oligonucleotide: GAATGAGCCGCAACT TCGGGAT. The 22-base oligonucleotide, without a Topo III cleavage site, was the following subsequence of the 45-base oligonucleotide: CAGAATCAGAATGAGCCGCAAC. Several exposures of the autoradiographs were quantified using a LKB-Pharmacia Ultrascan laser densitometer (in the case where a particular lane(s) were hard to visualize). In addition, bands from the gels, representing the indicated topoisomerase-oligonucleotide complex, were also excised, and the amount of radiolabeled oligonucleotide was determined using a Beckman LS 5801 liquid scintillation counter.

Topoisomerase-induced DNA Cleavage Assay

Reaction mixtures (5 µl) contained 40 mM Hepes-KOH buffer (pH 8.0 at 22 °C), 0.1 mg/ml bovine serum albumin, 1 mM magnesium acetate (pH 7.0), and 30 fmol of radiolabeled oligonucleotide. Topo III was incubated for 3 min at 37 °C, and the reaction was stopped by the addition of SDS to 2%. The reactions were adjusted to 45% formamide, 10 mM EDTA, 0.025% bromphenol blue, 0.025% xylene cyanol and heat-denatured for 5 min at 90 °C. The reaction products were separated by electrophoresis through a polyacrylamide gel (19:1) containing 50% w/v urea. The gels were then dried and autoradiographed.

Nuclease P1 Protection Assay

Reaction mixtures (5 µl) contained 40 mM Hepes-KOH buffer (pH 8.0 at 22 °C), 0.1 mg/ml bovine serum albumin, 1 mM magnesium acetate (pH 7.0), and 200 fmol of the radiolabeled oligonucleotide. Topo III was incubated for 3 min at 37 °C followed by addition of 3 times 10 units of P1 nuclease. The reactions were incubated an additional 10 min at 37 °C and terminated by the addition of EDTA to 10 mM. The reactions were adjusted to 45% formamide, 0.025% bromphenol blue, 0.025% xylene cyanol and heat denatured for 5 min at 90 °C. The reaction products were separated by electrophoresis through a polyacrylamide gel (19:1) containing 50% (w/v) urea. The gels were then dried and subjected to autoradiography.


RESULTS

Determination of the Minimum Substrate Required for Topo III-catalyzed Cleavage

The minimal sequence requirement of Topo III was determined by incubating the enzyme with oligonucleotides of various lengths and assessing the ability of the enzyme to cleave the substrate at the appropriate site. The oligonucleotides were designed to vary the length of DNA sequence both 5` and 3` of a strong Topo III cleavage site(16) . Substrates as short as 7 bases were capable of being cleaved by Topo III; however, the length of sequence 5` to the cleavage was critical in determining whether the enzyme could productively interact with the substrate.

Oligonucleotides, containing 5, 6, or 7 bases 5` of the cleavage site and 1 or 2 bases 3` to the cleavage site, were incubated with Topo III, and the cleavage products were resolved by electrophoresis through a polyacrylamide gel in the presence of urea (Fig. 1). When Topo III was incubated with a 9-base oligonucleotide containing 7 bases 5` of the major cleavage site, a major 7-base (corresponding to the previously identified cleavage site(16) ) and a minor 6-base cleavage product were observed (lane1). Incubation of Topo III with an 8-base oligonucleotide, containing 7 bases 5` and only one base 3` of the same major cleavage site, resulted in the production of identical cleavage products, although the 7-base cleavage product was diminished by 4.3-fold (lane3). This data clearly establishes the minimal 3`-sequence requirement for Topo III to be only 1 base.


Figure 1: Determination of the minimum substrates required for Topo III-catalyzed cleavage of single-stranded DNA. DNA cleavage experiments were performed using oligonucleotides containing either 7+2 bases (lanes1 and 2; where 7+2 indicates 7 bases 5` and 2 bases 3` of the cleavage site, respectively), 7+1 bases (lanes3 and 4), 6+2 bases (lanes5 and 6), 6+1 bases (lanes7 and 8), and 5+2 bases (lanes9 and 10). Reactions contained either 1 pmol of Topo III (lanes1, 3, 5, 7, 9) or no enzyme (lanes2, 4, 6, 8, 10). The reaction products were separated through a 25% polyacrylamide gel containing 50% (w/v) urea as described under ``Materials and Methods.''



To establish the 5`-minimal sequence requirement for Topo III-catalyzed cleavage, the enzyme was incubated with an 8-base oligonucleotide containing 6 bases 5` of the major cleavage site. This reaction resulted in the production of the 6-base cleavage product; however, the expected 5-base minor cleavage product (observed in the reaction containing the oligonucleotide with 7 bases 5` of the cleavage site) was absent (compare lane3 with lane5). This result suggested that the minimal 5`-sequence requirement for cleavage was 6 bases. This conclusion was confirmed by incubating Topo III with a 7-base oligonucleotide containing the predicted minimal site of 6 bases 5` of the cleavage site (lane7) and with a 7-base oligonucleotide containing only 5 bases 5` of the cleavage site (lane9). A 6-base cleavage product was observed in the case of the former (although the cleavage was reduced 9.3-fold relative to the substrate containing 6 bases 5` and 2 bases 3` of the cleavage site (lane5) and reduced 4.8-fold relative to the substrate containing 7 bases 5` and 1 base 3` of the cleavage site (lane3)), but no 5-base cleavage product was observed for the latter oligonucleotide. A summary of the cleavage experiments performed with multiple oligonucleotides is presented in Fig. 2.


Figure 2: Summary of the minimal substrate requirement for Topo III-catalyzed cleavage of single-stranded DNA. Topo III was incubated with the indicated oligonucleotides. The cleavage reactions were processed as previously described(16) , and the results are summarized here. A (+) indicates cleavage, and(-) indicates no cleavage. The total length of the oligonucleotide, as well as the length both 5` and 3` of the cleavage site, are indicated. The minimal substrate is indicated by the rectangle below the DNA sequence.



To further establish whether the minimal substrate was an actual characteristic of the enzyme rather than a peculiarity of the substrate, the minimal substrate requirement for Topo III-catalyzed cleavage was determined for two other independent cleavage sites. The minimal substrate requirement was identical using the different oligonucleotide substrates (data not shown).

Topoisomerase III Protects a 14-Base Region Surrounding the Cleavage Site from Nuclease Digestion

To elucidate whether the asymmetric nature of the minimal sequence requirement was reflected in the way Topo III binds to its substrate, an attempt was made to footprint Topo III using the 45-base oligonucleotide shown in Fig. 2as a substrate (Fig. 3). A titration of Topo III revealed a distinct protection pattern that surrounded the cleavage site. Consistent with the minimal substrate experiments, the protected region was asymmetric relative to the cleavage site, encompassing 12 bases 5` to the cleavage site to 2 bases 3` to the cleavage site.


Figure 3: Topoisomerase III protects a 14-base region, surrounding its cleavage site, from nuclease digestion. Nuclease P1 protection reactions were performed as described under ``Materials and Methods.'' The reaction products were resolved through a 25% polyacrylamide gel containing 50% (w/v) urea. The reactions contained no Topo III (lane2) or 0.1 pmol (lane1), 0.25 pmol (lane3), 0.5 pmol (lane4), 1 pmol (lane5), or 2 pmol (lane6) of Topo III. The topoisomerase III-induced cleavage product was obtained by incubation in the absence of P1 nuclease (lane1). The solidbar indicates the position of the Topo III-induced footprint.



Topoisomerase III Is a Site-specific Binding Protein

Although the P1 nuclease protection experiment revealed that Topo III generated a distinct footprint, it was unclear whether the protection pattern was generated by site-specific binding of the enzyme or dependent solely upon catalysis. To address this question, the nuclease P1 protection pattern of a catalytically inactive mutant of Topo III, Topo III-phe328 (which possesses a phenylalanine substitution for tyrosine 328, the putative amino acid involved in strand breakage(16, 17) ), was compared to the protection pattern of the active enzyme (Fig. 4). Titration of the catalytically inactive mutant (lanes8-11) revealed a similar footprint to the active polypeptide (lanes2-5), indicating that Topo III is a cleavage site-specific binding protein. However, since the mutant polypeptide is inactive, the footprint of the mutant lacks the Topo III-induced cleavage product.


Figure 4: Comparison of the DNA protection patterns generated by active Topo III and a catalytically inactive mutant polypeptide. Nuclease P1 protection reactions were performed with either Topo III (lanes1-6) or Topo III-phe328 (lanes7-12) as described under ``Materials and Methods'' and separated through a 15% polyacrylamide gel in the presence of 50% (w/v) urea. Reactions contained no topoisomerase (lanes1 and 7) or 0.25 pmol (lanes2 and 8), 0.5 pmol (lanes3 and 9), 1 pmol (lanes4, 6, 10, and 12), or 2 pmol (lanes5 and 11) of topoisomerase. Nuclease P1 was either included (lanes1-5 and 7-11) or absent (lane6 and 12) from the reaction. The cleavage product present in lanes2-6 is the major Topo III cleavage site present in the oligonucleotide.



The Relaxation of Negatively Supercoiled DNA by Topoisomerase III Is Preferentially Inhibited by an Oligonucleotide Containing a Cleavage Site

The ability to detect a Topo III-dependent protection pattern surrounding a strong enzyme cleavage site suggested that interaction between the enzyme and its cleavage site served to stabilize the enzyme on its substrate. If this were the case, an oligonucleotide containing a strong Topo III cleavage site should be an effective inhibitor of catalysis. This question was addressed by comparing the ability of a 22-base oligonucleotide containing a strong Topo III cleavage site with a 22-base oligonucleotide without a cleavage site to serve as an inhibitor of Topo III-catalyzed relaxation of negatively supercoiled DNA (Fig. 5).


Figure 5: Inhibition of Topo III-catalyzed relaxation of supercoiled DNA. Upper panel, DNA cleavage assay of 22-base oligonucleotides. An oligonucleotide containing (lanes1-4) or lacking (lanes5-8) a strong Topo III cleavage site was incubated with no Topo III (lanes1 and 5) or 0.01 pmol (lanes2 and 6), 0.1 pmol (lanes3 and 7), or 1 pmol (lanes4 and 8) of Topo III. Reaction products were separated through a 25% polyacrylamide gel in the presence of 50% (w/v) urea as described under ``Materials and Methods.'' Lower panel, superhelical DNA relaxation assay of Topo III in the presence of increasing levels of oligonucleotide. DNA relaxation assays were performed in the presence (lanes2-6 and 8-12) or absence (lanes1 and 7) of oligonucleotides that either contained no Topo III cleavage site (lanes2-6) or contained a strong Topo III cleavage site (lanes8-12). The oligonucleotide/substrate ratios used in the reactions were: 4 (lanes2 and 8), 20 (lanes3 and 9), 100 (lanes4 and 10), 500 (lanes5 and 11), and 1000 (lanes6 and 12). OC, open circle (nicked or gapped circular) DNA; SC, negatively supercoiled circular DNA.



The 22-base oligonucleotides consisted of a subset of sequence derived from the 45-base oligonucleotide (shown in Fig. 2), which either contained (bases 9-30) or did not contain (bases 1-22) the cleavage site. The presence or absence of the cleavage site was confirmed by incubating the 22-base oligonucleotides with increasing levels of Topo III (Fig. 5, toppanel). It is clear that only one of the oligonucleotides contains a strong cleavage site.

Each oligonucleotide was then assessed for its ability to serve as an inhibitor of Topo III-catalyzed relaxation of negatively supercoiled DNA (Fig. 5, lowerpanel). Both oligonucleotides can serve an inhibitor of Topo III catalysis (presumably by acting as an alternate substrate). At oligonucleotide/substrate ratios of up to 20:1, the oligonucleotide containing the cleavage site (lanes8-12) was approximately five times more effective as an inhibitor than an oligonucleotide without such a site (lanes2-6). However, with greater oligonucleotide/substrate ratios, the oligonucleotide containing the cleavage site appeared to be 10-20 times more effective as an inhibitor than an oligonucleotide without a cleavage site (a 1000-fold excess of the oligonucleotide without the cleavage site (lane6) inhibits to a significantly lesser extent than a 100-fold excess of the oligonucleotide containing a cleavage site (lane10)).

Topoisomerase III Binds Preferentially to an Oligonucleotide Containing a Cleavage Site, and the Efficiency of Binding Is Length Dependent

The ability of Topo III to bind to the 45-base oligonucleotide shown in Fig. 2was directly compared to the 22-base oligonucleotides using an oligonucleotide mobility shift assay. An equimolar amount of all three oligonucleotides was incubated with increasing levels of Topo III, the products were resolved by native polyacrylamide gel electrophoresis, and the amount of oligonucleotide present in the stable oligonucleotide-topoisomerase complex was determined as described under ``Materials and Methods'' (Fig. 6). Consistent with previous results, the 22-base oligonucleotide containing a strong cleavage site was bound with a 4-5-fold preference to the 22-base oligonucleotide without the site (compare lanes7-10 with lanes12-15). The preferential binding of Topo III to its cleavage site appears to be independent of catalysis since the catalytically inactive polypeptide, Topo III-phe328, has the same substrate preference as the active enzyme (data not shown).


Figure 6: Oligonucleotide gel mobility shift assay of oligonucleotides containing or lacking a strong Topo III cleavage site. Oligonucleotides that either contained (lanes1-5 and lanes11-15) or lacked (lanes6-10) a strong Topo III binding/cleavage site were incubated with no Topo III (lanes1, 6, 11) or 0.4 pmol (lanes2, 7, 12), 1.2 pmol (lanes3, 8, 13), 3.6 pmol (lanes4, 9, 14), or 10.8 pmol (lanes5, 10, 15) of Topo III. The reactions were processed and resolved through a 10% polyacrylamide gel. The position of the stable topoisomerase-oligonucleotide complex is indicated. The amount of the topoisomerase-oligonucleotide complex was determined as described under ``Materials and Methods.'' The positions of the unbound 45-base and 22-base oligonucleotides are indicated.



Interestingly, the 45-base oligonucleotide (which contained the same cleavage site as the 22-base oligonucleotide) was bound far more efficiently than either of the 22-base oligonucleotides (compare lanes2-5 with 7-10 and 12-15). The decrease in binding efficiency observed with decreasing oligonucleotide length also appears to affect the amount of unbound oligonucleotide observed in this analysis. There is a concomitant increase in the amount of stable oligonucleotide-topoisomerase complex with the decrease of unbound oligonucleotide with the 45-base oligonucleotide substrate (lanes2-5); however, this is not observed for the smaller substrates. This is presumably due to the fact that unstable complexes formed with the smaller substrates disintegrate and reform during electrophoresis, resulting in a smear of products throughout the lane.

A 13-base oligonucleotide (a subsequence of the 45-base oligonucleotide) that did not show any evidence of interaction with Topo III (by footprint analysis) was also used as a substrate in a gel mobility shift assay. In accord with previous results, Topo III was capable of interacting with this substrate; however, the amount of stable topoisomerase-oligonucleotide complex was much lower than that formed with either the 22-base oligonucleotide or the 45-base oligonucleotide (data not shown). This length effect may be indicative of the mechanism by which Topo III locates its binding/cleavage site during catalysis.


DISCUSSION

The minimum substrate requirement for DNA topoisomerase III-catalyzed cleavage has been examined and found to consist of only 7 bases, asymmetrically encompassing a known cleavage site of the enzyme. Oligonucleotides containing as little a 1 base 3` of the cleavage site were cleaved by Topo III, establishing the minimal 3` requirement for the enzyme. An oligonucleotide containing 6 bases 5` of the cleavage site and 2 bases 3` of the cleavage site was also cleaved by Topo III; however, an oligonucleotide containing 5 bases 5` and 2 bases 3` of the site was not cleaved by the enzyme, establishing a 5`-sequence requirement of 6 bases. When a Topo III-induced cleavage assay was performed using the minimal substrate, cleavage was observed; however, it was reduced 9-fold when compared to the efficiency of cleavage of an oligonucleotide containing one more base 3` of the minimal sequence and reduced 5-fold when compared to an oligonucleotide containing one more base 5` of the minimal sequence.

The minimal sequence requirement for E. coli Topo I has previously been determined to be 7 or 8 bases(18, 19) , but the substrates used in these studies were homopolymers and not an actual cleavage site of the enzyme. In any event, it appears likely that the minimal substrate requirement for the two enzymes is similar. It is unclear, however, if Topo I will show the same asymmetric sequence requirement for cleavage as Topo III.

Nuclease P1 footprinting experiments indicate that the enzyme also binds asymmetrically to its substrate relative to its cleavage site. Topo III was shown to protect a region of the substrate from 12 bases 5` to the cleavage site to 2 bases 3` of the site. An identical footprint was observed using a polypeptide incapable of cleaving the substrate, illustrating that catalysis is not a requirement for cleavage site recognition. Topo III, therefore, is a cleavage site-specific binding protein as well as topoisomerase.

The highly asymmetric sequence requirement of Topo III is consistent with the known catalytic mechanism of prokaryotic topoisomerases. These enzymes cleave DNA by making a nucleophilic attack 5` to the phosphate in the phosphodiester backbone. In this mechanism, the topoisomerase becomes covalently linked to the DNA 3` to the cleavage site via an enzyme-bridged phosphotyrosine linkage (reviewed in (7) ). Since the enzyme is covalently bound to the 3`-DNA fragment, it is not surprising that there may be only a minimal sequence requirement in this region. In fact, these experiments suggest that the enzyme may only require a single nucleotide to serve as a receptor for the nucleophilic attack. To prevent free rotation about the strand scission, however, the enzyme must have considerable noncovalent interactions with the 5`-fragment. This is again consistent with the observed minimal substrate requirement of at least 6 bases 5` to the cleavage site.

The binding properties of Topo III are also reminiscent of a site-specific binding protein. First, an oligonucleotide containing a Topo III cleavage site is more efficiently bound by the enzyme than an oligonucleotide without a site. Second, an oligonucleotide containing a cleavage site is a better inhibitor of Topo III-catalyzed relaxation of negatively supercoiled DNA than an oligonucleotide lacking a cleavage site. Although gel mobility shift experiments indicate that substrates containing a cleavage site are bound more efficiently by the enzyme, Topo III is also capable of interacting with substrates that do not contain a cleavage site. These properties suggest a model for Topo III-catalyzed cleavage of DNA (Fig. 7).


Figure 7: Model of DNA topoisomerase III-catalyzed cleavage of single-stranded DNA. The proposed mechanism of Topo III-mediated cleavage of DNA is presented. The reaction has been separated into three distinct steps (A-C). Briefly, Topo III (represented by the oval) binds randomly to single-stranded DNA. The enzyme then diffuses or tracks (arrows) along its substrate until it encounters a binding/cleavage site (diagonallyfilledrectangle). The enzyme forms a stable complex with its cleavage site through interactions within the active site of the enzyme and then catalyzes a transient break in the single-stranded DNA (the triangle represents the active site tyrosine residue). A detailed explanation of the model is given in the text.



In the first stage of interaction (which we term generalized binding), Topo III binds randomly along its substrate molecule (Fig. 7A). This is consistent with the finding that Topo III can bind to substrates with and without cleavage sites. This model would predict a length dependence of the binding reaction since, in a nonspecific binding interaction, a longer oligonucleotide provides a larger target site per mole of substrate than a smaller oligonucleotide. Once bound to the substrate, the enzyme diffuses, or tracks, along the DNA until it encounters a binding/cleavage site.

Locating a specific binding site via a nondirectional tracking process has been ascribed to Topo III because there is no evidence of a nucleoside triphosphate hydrolysis-driven directional search by these enzymes. In principle, a directional search is a more efficient mechanism to locate sequences that are relatively distant from one another, but the location of both Topo III and Topo I cleavage sites has been found to be, on average, only 10-20 nucleotides apart(4, 20) . The relative abundance of these sites may not require a directional search.

Although the tracking-mediated search proposed in this model is consistent with our experimental results, kinetic experiments will be required to elucidate the actual mechanism by which Topo III locates its binding/cleavage site. Oligonucleotide mobility shift assays only give information on equilibrium binding; therefore, the length effect observed in our experiments, while consistent with the model, is only indicative of the more stable binding of Topo III to the longer oligonucleotide than to the shorter oligonucleotide.

In the second stage of the reaction (which we term sequence recognition and stabilization), the enzyme recognizes and forms a stable complex with its cleavage site (Fig. 7B). In this stage, interactions with amino acids near or within the active site of the enzyme stabilize the enzyme-DNA complex and properly position the substrate within the active site (as illustrated by the ability to generate a nuclease P1 footprint). Positioning of the substrate within the active site is independent of the generalized binding of the substrate since truncations within the carboxyl terminus that drastically reduce the enzyme's binding affinity (>99%) do not alter cleavage site selection by the enzyme(16) .

In the final stage of the reaction (which we term asymmetric cleavage), the enzyme cleaves the substrate (Fig. 7C). During this step of catalysis, the majority of noncovalent interactions occur with DNA 5` to the cleavage site, with only minimal interactions occurring 3` to the site.

The model above has been derived using data obtained from studies using small, single-stranded DNA oligonucleotides as model substrates. These observations can be extended to physiologically relevant reactions catalyzed by topoisomerase III upon double-stranded substrates. Topo III is a single-stranded DNA binding protein with a relatively low affinity for double-stranded DNA(16) ; therefore, Topo III-catalyzed relaxation of negatively supercoiled DNA would require the enzyme to recognize and bind to single-stranded regions present in a negatively supercoiled, predominantly double-stranded molecule. The presence of single-stranded regions within a covalently closed DNA substrate is influenced by the superhelical density of the molecule, the local base composition within the molecule, and the reaction conditions. The optimum reaction conditions for Topo III-catalyzed relaxation activity (i.e. low magnesium optimum and stimulation by high temperatures(4) ) favor the formation of single-stranded DNA and are consistent with this interpretation.

In the case of the decatenation of multiply interlinked plasmid DNA molecules, the enzyme would bind to small single-stranded regions present in the replicated DNA. These regions would be a consequence of lagging strand DNA synthesis, particularly from the removal of the small RNA primers used to initiate DNA synthesis. This is also consistent with the finding that the decatenation of isolated plasmid DNA dimers by Topo III is dramatically stimulated by the presence of small gaps within the substrate(4) .

In this report, we have addressed only a half-reaction in the total scheme of topoisomerase catalysis. There is very little known about the next step of catalysis, strand passage. We are in the process of trying to isolate mutants that affect the strand passage reaction in the hope of being able to further dissect the mechanism of topoisomerase III.


FOOTNOTES

*
These studies were supported by Grant GM48445-02 from the National Institutes of Health (to R. J. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed.

(^1)
The abbreviation used is: Topo, topoisomerase.


ACKNOWLEDGEMENTS

We thank Drs. M. Speedie, K. Reynolds, and K. Marians for the critical reading of the manuscript.


REFERENCES

  1. Wang, J. C. (1971) J. Mol. Biol. 55,523-533 [Medline] [Order article via Infotrieve]
  2. Pastorcic, M. (1982) Purification and Characterization of a New Type I Topoisomerase in E. coli . Ph.D. Thesis, University of Chicago
  3. Srivenugopal, K. S., Lockshon, D., and Morris, D. R. (1984) Biochemistry 23,1899-1906 [Medline] [Order article via Infotrieve]
  4. DiGate, R. J., and Marians, K. J. (1988) J. Biol. Chem. 263,13366-13373 [Abstract/Free Full Text]
  5. Gellert, M., Mizuuchi, K., O'Dea, M., and Nash, H. (1976) Proc. Natl. Acad. Sci. U. S. A. 73,3872-3876 [Abstract]
  6. Kato, J.-I., Nishimura, Y., Imamura, R., Niki, H., Hiraga, S., and Suzuki, H. (1990) Cell 63,393-404 [Medline] [Order article via Infotrieve]
  7. Wang, J. C. (1985) Annu. Rev. Biochem. 54,665-698 [CrossRef][Medline] [Order article via Infotrieve]
  8. Steck, T., and Drlica, K. (1984) Cell 36,1081-1088 [CrossRef][Medline] [Order article via Infotrieve]
  9. Adams, D. E., Shekhtman, E. M., Zechiedrich, E. L., Schmid, M. B., and Cozzarelli, N. R. (1992) Cell 71,277-288 [Medline] [Order article via Infotrieve]
  10. Peng, H., and Marians, K. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,8571-8575 [Abstract/Free Full Text]
  11. Hiasa, H., DiGate, R. J., and Marians, K. J. (1994) J. Biol. Chem. 269,2093-2099 [Abstract/Free Full Text]
  12. Hiasa, H., and Marians, K. J. (1994) J. Biol. Chem. 269,32655-32659 [Abstract/Free Full Text]
  13. Brown, P. O., and Cozzarelli, N. R. (1979) Science 206,1081-1083 [Medline] [Order article via Infotrieve]
  14. Dean, F. B., and Cozzarelli, N. R. (1985) J. Biol. Chem. 260,4984-4994 [Abstract]
  15. Liu, L. F., and Wang, J. C. (1978) Cell 15,979-984 [Medline] [Order article via Infotrieve]
  16. Zhang, H. L., and DiGate, R. J. (1994) J. Biol. Chem. 269,9052-9059 [Abstract/Free Full Text]
  17. DiGate, R. J., and Marians, K. J. (1989) J. Biol. Chem. 264,17924-17930 [Abstract/Free Full Text]
  18. Tse-Dinh, Y.-C., McMarron, B. G., Arentzen, R., and Chowdhry, V. (1983) Nucleic Acids Res. 11,8691-8701 [Abstract]
  19. Domanico, P. L., and Tse-Dinh, Y.-C. (1988) Biochemistry 27,6365-6371 [Medline] [Order article via Infotrieve]
  20. Dean, F. B. (1984) Studies on the Mechanism of Escherichia coli Topoisomerase I . Ph. D. Thesis, University of Chicago

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.